Clinical Precision. Innovated.

Advanced algorithms to power neuroimaging biomarker extraction in clinical studies

Find out more »

Pixyl delivers quantitative neuroimaging biomarker extraction for improved insight and decision-making in clinical studies. Our automatic neuroimaging solutions are designed for seamless integration into both web-based and locally deployed CRO platforms. Advanced algorithms are available for multiple sclerosis, chronic stroke, and traumatic brain injury applications.


Efficient time management for image reviewers


Objective analysis reduces variability across entire study database for better decision-making


Correlated with expert opinion


Longitudinal studies to assess treatment efficacy. Consistent quantitative results for quality assurance

Pixyl was founded in 2015 to deliver precise neuroimaging biomarker extraction for improved insight and decision-making in clinical studies and routine clinical practice.

Our automatic neuroimaging segmentation plugins are designed for seamless integration into the workflows of imaging CROs, neuroradiologists and neurologists.

Pixyl powers the next-generation of medical image analysis platforms. In clinical research and routine practice, our novel analysis engines advance the diagnostic and prognostic potential, and develop the medical treatments of the future.

Our technology was developed through successive collaboration between Inria Grenoble Rhône-Alpes and Inserm (Grenoble Institute of Neuroscience), beginning in 2008.
Senan Doyle, Ph.D.
CEO & Co-founder
With a strong background in Bayesian methods, Senan helped develop the registration and segmentation algorithms that form the core Pixyl technology. He previously worked as a medical image analysis researcher at INRIA Grenoble Rhône-Alpes and the Grenoble Institute of Neuroscience (INSERM). He holds a Ph.D. in electronic engineering from the University of Dublin, Trinity College.
Michel Dojat, Ph.D.
Scientific Advisory Board & Co-founder
An expert in medical image analysis and functional neuroimaging, Dr. Dojat's research interests currently include neuroimage processing and data management, and the exploration of human visual system via fMRI. Dr. Dojat is a senior IEEE member, on the editorial board of 'Artificial Intelligence in Medicine', and an active reviewer for many top-tier international journals and conferences.
Florence Forbes, Ph.D.
Scientific Advisory Board & Co-founder
Director of research at INRIA and head of the MISTIS team since 2003, Dr. Forbes has worked for 20 years on probabilistic graphical models, clustering methods, spatial data analysis and statistical image analysis. Publications in international journals and conferences relate to 4 main fields: Statistics and Probability, Machine learning and Shape recognition, Image Processing and Signal Processing, Biology and Medicine.
Prof. Alexandre Krainik, PU-PH, CHU de Grenoble, Clinique Universitaire De Neuroradiologie et Imagerie par Résonance Magnétique et UMS IRMAGE.
Dr. Olivier Detante, PH, CHU de Grenoble, Unité de Neurologie Vasculaire.
Dr. Assia Jaillard, PH, CHU de Grenoble, IRMAGE
Prof. Jean-François Payen, PU-PH, CHU de Grenoble, Pôle Anesthésie Réanimation.

Journées Francophones de Radiologie

Pixyl will be at stand 102, demonstrating how our advanced algorithms deliver precise neuroimaging biomarker extraction for improved insight and decision-making in clinical studies.

"Quantitative MRI for neuroradiology" Workshop, Lausanne

Dr. Florence Forbes presents "Automatic brain lesion segmentation: methodological challenges" at 13h15.

Graine d'Entrepreneurs

INRIA celebrates 30 years of industrial transfer. Pixyl is one of the latest startups to emerge from their laboratories.

Medicalps Healthcare Cluster

Pixyl joins the Medicalps healthcare industry cluster

Pixyl demo at CLUTAV 2015


Pixyl demo at SFRMBM 2015


Pixyl created


Pixyl accompanied by IT Translation


Pixyl awarded the 2014 BpiFrance Emergence Grant


Prof. Jean-François Payen

Pôle Anesthésie-Réanimation. CHU Grenoble

"Pixyl has been selected for the randomized trial OxyTC that I coordinate on a national level (PHRC National 2013).This multicenter study comprises of 23 sites and 300 patients who have serious traumatic brain injury. The purpose of the study is to measure the effect of brain oxygenation optimization on brain lesion volume (primary endpoint)."

Dr. Olivier Detante

PH Responsable Unité Neuro-Vasculaire. CHU Grenoble

"Numerous studies suggest that lesion volume should be a biomarker for neurological recovery. Indeed, lesion volume, whether or not it is associated with neurological deficiency, is an independent predictor of recovery.
Recent development of high resolution MRI sequences allows for a more precise analysis of lesions, and this further motivates the study of stroke lesion volume. However, even with these developments, volume measurement requires manual delineation. This is a long task, difficult to reproduce, and unthinkable for large study populations.
Even though other segmentation software claims to perform automatic delineation, none have been validated or seem usable in routine. That's why we contributed to the development of Pixyl software solutions that allow automatic, fast and precise delineation of cerebral infarction."


    * Required

Investors and Partners